Harrow, Inc. announced a partnership with Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). This product treats and relieves bacterial eye infections, expanding Harrow's generic portfolio.
According to IQVIA data as of January 2025, Maxitrol and its generic equivalents had annual sales of $20.8 million in the U.S. This launch provides patients with another affordable prescription option in the ophthalmic market. The collaboration leverages Harrow's expertise as a leading North American eyecare company.
Thomas Sammler, VP Commercial Operations at Nordic Pharma, stated that this launch is the culmination of months of work to bring this new authorized generic to the marketplace. The addition of this product is expected to contribute to Harrow's mission of making pharmaceutical products accessible and affordable.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.